We are live on ! Find out more
RPAM

Rhenman & Partners Asset Management Portfolio holdings

AUM $810M
1-Year Est. Return 30.2%
This Fund
S&P 500
This Quarter Est. Return
+2.06%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$342M
AUM Growth
+$4.53M
Cap. Flow
+$2.54M
Cap. Flow %
0.74%
Top 10 Hldgs %
27.24%
Holding
105
New
9
Increased
44
Reduced
37
Closed
6

Top Buys

Rank Stock Value
1
MDT icon
Medtronic
MDT
+$8.51M
2
UHS icon
Universal Health Services
UHS
+$7.3M
3
ABBV icon
AbbVie
ABBV
+$6.16M
4
RAD
Rite Aid Corporation
RAD
+$5.54M
5
ICPT
Intercept Pharmaceuticals, Inc.
ICPT
+$4.74M

Top Sells

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$10.6M
2
COV
COVIDIEN PLC COM SHS NEW (IRELAND)
COV
+$8.41M
3
CELG
Celgene Corp
CELG
+$6.93M
4
BIIB icon
Biogen
BIIB
+$6.92M
5
ALXN
Alexion Pharmaceuticals
ALXN
+$5.75M

Sector Composition

Rank Sector Weight
1 Healthcare 78.72%
2 Financials 1.38%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
KERX
76
DELISTED
Keryx Biopharmaceuticals Inc
KERX
$1.87M 0.55%
136,000
-104,000
-43% -$1.59M
AFL icon
77
Aflac
AFL
$62.6B
$1.86M 0.55%
64,000
-7,000
-10% -$213K
SUPN icon
78
Supernus Pharmaceuticals
SUPN
$2.77B
$1.84M 0.54%
212,000
-15,000
-7% -$135K
LGND icon
79
Ligand Pharmaceuticals
LGND
$6.36B
$1.83M 0.54%
62,517
-4,809
-7% -$160K
CLDX icon
80
Celldex Therapeutics
CLDX
$3.28B
$1.79M 0.52%
9,200
-4,067
-31% -$886K
MGNX icon
81
MacroGenics
MGNX
$257M
$1.78M 0.52%
85,000
+25,000
+42% +$517K
DVAX
82
DELISTED
Dynavax Technologies
DVAX
$1.76M 0.51%
122,835
– –
SYK icon
83
Stryker
SYK
$130B
$1.7M 0.5%
21,000
+6,000
+40% +$494K
JAZZ icon
84
Jazz Pharmaceuticals
JAZZ
$16.7B
$1.61M 0.47%
+10,000
New +$1.54M
TSRO
85
DELISTED
TESARO, Inc.
TSRO
$1.48M 0.43%
55,000
– –
VIRX
86
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$1.44M 0.42%
958
– –
ARRY
87
DELISTED
Array Biopharma Inc
ARRY
$1.35M 0.4%
379,199
+50,000
+15% +$197K
ALNY icon
88
Alnylam Pharmaceuticals
ALNY
$29.3B
$1.02M 0.3%
+13,030
New +$841K
BIND
89
DELISTED
BIND THERAPEUTICS INC
BIND
$932K 0.27%
108,535
– –
ANTH
90
DELISTED
Anthera Pharmaceuticals, Inc.
ANTH
$768K 0.22%
50,000
+12,500
+33% +$263K
EXEL icon
91
Exelixis
EXEL
$13.4B
$765K 0.22%
500,000
+200,000
+67% +$642K
OCR
92
DELISTED
OMNICARE INC
OCR
$623K 0.18%
10,000
-18,500
-65% -$1.18M
VOLC
93
DELISTED
VOLCANO CORPORATION COM STK
VOLC
$470K 0.14%
44,221
– –
MTEM
94
DELISTED
Molecular Templates, Inc.
MTEM
$439K 0.13%
737
– –
LXRX icon
95
Lexicon Pharmaceuticals
LXRX
$1.1B
$416K 0.12%
42,115
– –
SRNE
96
DELISTED
Sorrento Therapeutics, Inc.
SRNE
$328K 0.1%
72,535
– –
ECYT
97
DELISTED
Endocyte, Inc. Common Stock
ECYT
$300K 0.09%
49,297
– –
HAE icon
98
Haemonetics
HAE
$4B
– –
-10,047
Closed -$354K
ISRG icon
99
Intuitive Surgical
ISRG
$134B
– –
-22,500
Closed -$1.03M
MYGN icon
100
Myriad Genetics
MYGN
$312M
– –
-80,000
Closed -$3.11M
1 2 3
4
5

Similar funds

PS
Portfolio Strategies Monsey, New York $811M AUM 28.91% 1-Year Est. Return
ACM
Ashford Capital Management Wilmington, Delaware $809M AUM 35.1% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return
KCP
Kera Capital Partners San Jose, California $815M AUM 46.39% 1-Year Est. Return
BCM
Brigade Capital Management New York $806M AUM 20.71% 1-Year Est. Return
RIM
Redwood Investment Management Scottsdale, Arizona $805M AUM 15.01% 1-Year Est. Return
GCM
Glendon Capital Management Santa Monica, California $805M AUM 17.91% 1-Year Est. Return
CL
CVFG LLC Shelbyville, Indiana $804M AUM 27.61% 1-Year Est. Return

Rhenman & Partners Asset Management's Q3 2014 Portfolio in Review

As of Q3 2014, Rhenman & Partners Asset Management held 105 positions worth $342M, up 1.3% from $337M the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rhenman & Partners Asset Management's Q3 2014 filing shows 9 new, 44 increased, 37 reduced and 6 closed positions. Its largest new stake was Medtronic: 133,800 shares worth $6.87M. The largest sale was Gilead Sciences, an estimated $10.6M.

By sector, the portfolio is most concentrated in Healthcare at 79% of assets, down from 85% a quarter earlier, followed by Financials.

  • Rhenman & Partners Asset Management's largest Q3 2014 buy was Medtronic: 133,800 shares worth $6.87M.
  • Rhenman & Partners Asset Management added most to Universal Health Services in Q3 2014, an estimated $7.3M increase.
  • Rhenman & Partners Asset Management's biggest Q3 2014 reduction was Gilead Sciences, cutting an estimated $10.6M.
  • Rhenman & Partners Asset Management fully exited Myriad Genetics in Q3 2014, selling an estimated $3.11M.
  • Rhenman & Partners Asset Management's ten largest holdings make up 27% of its $342M portfolio in Q3 2014.
  • Rhenman & Partners Asset Management opened 9 new positions and closed 6 in Q3 2014.
  • Rhenman & Partners Asset Management's portfolio value rose 1.3% quarter-over-quarter to $342M.

Based on Rhenman & Partners Asset Management's 13F filing for Q3 2014, filed 3 Nov 2014.